Instem has developed Advance™ a NEW technology-enabled approach for assessing carcinogenicity based on the recently published ICH S1B Weight of Evidence (WoE) Addendum. If a WoE can be utilized, it can deliver huge benefits to organizations throughout the R&D pipeline including:

• Significantly decreasing animal usage in line with the 3Rs initiative.
• Potential to save $2-4 million in costs associated with the drug discovery process.
• Empowering researchers with the confidence to progress drugs to market faster, reducing time to market by 3 - 5 years.

The Advance™ solution includes a comprehensive technology enabled carcinogenicity assessment report that mirror the six guideline-based WoE factors.

1. Target Biology
2. Secondary Pharmacology
3. Histopathology
4. Hormonal Perturbation
5. Genetic Toxicology
6. Immune Modulation

Advance™ provides organizations with comprehensive, industry approved, evidence-based carcinogenicity assessments, enabling them to streamline their WoE submissions and ultimately get their life-enhancing products to market faster.

Client Testimony

"The Advance™ services are a living embodiment of more than a decade of effort from scientists and regulators across the globe. We now have an avenue for leveraging a scientific-based argument to reduce the emphasis on animal use in the post marketing space without compromising patient safety. It’s an opportunity for us to embrace innovation and to deliver medicines in a more efficient way."
Advance™ Client - Global Pharma Organization

• Advance™ Weight of Evidence Assessments Download the Fact Sheet
• Instem Enables Clients to Leverage ICH S1B Weight of Evidence Guideline Read the Press Release
• Webcast - From Safety Testing to Success: ICH S1B and the Power of Data Sharing Watch the Webcast